Soluble Prion Protein Binds Isolated Low Molecular Weight Amyloid-β Oligomers Causing Cytotoxicity Inhibition
Thomas L Williams1, Jin-Kyu Choi1, Krystyna Surewicz1
1Department of Physiology and Biophysics, Case Western Reserve University , Cleveland, Ohio 44106, United States.
Abstract:
A growing number of observations indicate that soluble amyloid-β (Aβ) oligomers play a major role in Alzheimer's disease. Recent studies strongly suggest that at least some of the neurotoxic effects of these oligomers are mediated by cellular, membrane-anchored prion protein and that Aβ neurotoxicity can be inhibited by soluble recombinant prion protein (rPrP) and its fragments. However, the mechanism by which rPrP interacts with Aβ oligomers and prevents their toxicity is largely unknown, and studies in this regard are hindered by the large structural heterogeneity of Aβ oligomers. To overcome this difficulty, here we used photoinduced cross-linking of unmodified proteins (PICUP) to isolate well-defined oligomers of Aβ42 and characterize these species with regard to their cytotoxicity and interaction with rPrP, as well the mechanism by which rPrP inhibits Aβ42 cytotoxicity. Our data shows that the addition of rPrP to the assembling Aβ42 results in a shift in oligomer size distribution, decreasing the population of toxic tetramers and higher order oligomers and increasing the population of nontoxic (and possibly neuroprotective) monomers. Isolated oligomeric species of Aβ42 are cytotoxic to primary neurons and cause permeation of model lipid bilayers. These toxic effects, which are oligomer size-dependent, can be inhibited by the addition of rPrP, and our data suggest potential mechanisms of this inhibitory action. This insight should help in current efforts to develop PrP-based therapeutics for Alzheimer's disease.
Insights
Soluble prion protein (rPrP) prevents toxic amyloid-β (Aβ) oligomers in Alzheimer's disease by altering their size and reducing neurotoxicity. This interaction offers potential therapeutic strategies for Alzheimer's disease.
Area of Science:
- Neuroscience
- Biochemistry
- Molecular Biology
Background:
- Soluble amyloid-β (Aβ) oligomers are implicated in Alzheimer's disease pathogenesis.
- Cellular prion protein mediates Aβ oligomer neurotoxicity.
- Recombinant prion protein (rPrP) can inhibit Aβ neurotoxicity, but the mechanism is unclear.
Purpose of the Study:
- To investigate the mechanism by which rPrP interacts with and inhibits Aβ42 oligomer cytotoxicity.
- To characterize well-defined Aβ42 oligomers and their toxic effects.
Main Methods:
- Photoinduced cross-linking of unmodified proteins (PICUP) to isolate homogeneous Aβ42 oligomers.
- Assessment of Aβ42 oligomer cytotoxicity on primary neurons and model lipid bilayers.
- Evaluation of rPrP's effect on Aβ42 oligomer size distribution and toxicity.
Main Results:
- rPrP addition shifts Aβ42 assembly towards non-toxic monomers, reducing toxic tetramers and higher-order oligomers.
- Isolated Aβ42 oligomers exhibit size-dependent cytotoxicity and disrupt lipid bilayers.
- rPrP effectively inhibits Aβ42-induced cytotoxicity and membrane permeation.
Conclusions:
- rPrP modulates Aβ42 oligomerization, mitigating their neurotoxic potential.
- Understanding the rPrP-Aβ interaction provides insight into Alzheimer's disease mechanisms.
- This study supports the development of PrP-based therapeutics for Alzheimer's disease.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils


